DXR CEO Feldschuh Michael Richard Buys 30,000 Shares
CEO Michael Feldschuh has increased his stake in DXR with a 30,000-share purchase.
Reviewed by automated data checks against the source filing. How we make and check alerts
Feldschuh Michael Richard, Chief Executive Officer at DXR ($DXR), bought 30,000 shares on June 23, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $DXR is up 1.5% after 1 week, up 5.6% after 1 month and down 0.9% to date (from the $10.14 close on Jun 23, 2026).
DXR
DXR
Key Points
- On June 23, 2026, DXR's CEO Michael Feldschuh bought 30,000 shares, signaling strong insider confidence.
- Shares of DXR were trading at $10.32 on Friday, with multiple institutional investors opening new positions.
- Analysts from Ascendiant Capital and Maxim Group maintain 'buy' ratings with price targets ranging up to $25.
Get $DXR trade alerts by text
We text you when insiders, Congress or big funds trade $DXR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated DXR alert may contain errors. Disclosures
On June 23, 2026, DXR's Chief Executive Officer, Michael Feldschuh, purchased 30,000 shares of the company. This insider transaction did not occur under a pre-planned trading scheme, indicating a direct decision by Feldschuh to increase his stake in the company.
Other Institutional Activity in DXR
Several institutional investors have recently opened new positions in DXR. Thompson Siegel & Walmsley LLC initiated a stake with 232,120 shares valued at approximately $2.25 million. Vanguard Capital Management LLC also opened a new position, acquiring 48,280 shares worth about $469,282. Similarly, Aristides Capital LLC entered with 41,692 shares valued at $403,162. Meanwhile, Renaissance Technologies LLC slightly reduced its holdings by 210 shares, ending with 28,011 shares valued at $270,866.
DXR Stock Snapshot
Shares of DXR traded at $10.32 on Friday. The stock has seen various institutional investments, indicating interest in its potential. However, specific financial metrics such as market cap or P/E ratio were not available for a detailed snapshot.
Insider Buying and Selling at DXR
Alongside Michael Feldschuh's purchase, other insiders have been active in buying shares. Caleb Desrosiers, Robert Michel (CFO), Joy Goudie, Henry Cremisi, Jonathan Feldschuh (Chief Scientific Officer), and Edward Feuer all bought shares on June 23, 2026. Notably, Jonathan Feldschuh acquired 25,000 shares, while Robert Michel purchased 12,000 shares, reflecting a broad insider confidence in the company's prospects.
Analysts Set New Price Targets
Analysts remain optimistic about DXR. On March 17, 2025, Ascendiant Capital maintained its 'buy' rating with a price target of $25. Maxim Group reiterated its 'buy' rating with a $22 target on March 27, 2024. These ratings suggest continued confidence from analysts in DXR's future performance.
Bottom Line
DXR's CEO and other insiders have shown confidence by purchasing shares, while multiple institutional investors have opened new positions. Analysts are maintaining positive ratings, with price targets that suggest potential upside. However, as with all 13F filings and insider transactions, these actions reflect past decisions and may not indicate current positions.
Related Filing Alerts
Source: Feldschuh Michael Richard's Form 4 filing on $DXR (Jun 23, 2026). Find the original filing: DXR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts